Category Archives: News

Joget Introduces Agent Lab, a Program Helping Businesses Build AI Agents Without Code

New community initiative invites businesses to submit real workflow challenges for a free, expert-built AI agent, with selected builds shown live in an exclusive webinar.

COLUMBIA, Md., Aug. 26, 2026 /PRNewswire/ — Joget, Inc., the global innovator of the open-source, enterprise agentic AI application platform, today announced the launch of Joget Agent Lab, a community-driven initiative that builds a working AI agent for selected businesses at zero cost.

Any organisation can submit a bottleneck or manual process, along with how they’d want an agent to solve it, through the Agent Lab submission form. Joget’s product team reviews the entries, selects the strongest use cases, and builds and tests a working prototype for each one.

The finished agents are then unveiled in a live webinar, where Joget walks through the build step by step, including the prompts and tools used, so participants leave knowing exactly how to attempt the same build themselves.

“We hear the same thing from businesses across every industry: they know exactly where AI could save them time, but building an agent still feels like something you need a developer for,” said Raveesh Dewan, President and CEO of Joget.

“Agent Lab takes that assumption apart in public. We build the agent, we show our work, and by the end of the webinar you know how to do it yourself on our platform.”

Joget Agent Lab is open to:

• Business leaders and managers looking to automate repetitive tasks and free up their teams
• IT professionals and developers exploring how quickly they can prototype AI agents on a live platform
• Process owners and analysts searching for a practical fix to a workflow that has outgrown manual handling

How it works

1. Submit an idea. 
   
   Describe a bottleneck or manual process, and how an agent could solve it.
   
   
   
   
2. Joget builds it. 
   
   The product team reviews submissions and prototypes an agent for the ideas selected.
   
   
   
   
3. Watch it live. 
   
   Participants join a webinar to see the finished build and learn how to replicate it.

The agents built through the programme run on Joget AI Agent Builder, a no-code tool that lets both technical and non-technical users design agents visually, test them before deployment, and keep a human in the loop for approval.

Businesses looking to move faster on app development more broadly can pair this with Joget AI Composer, which builds and edits forms, lists, workflows, and interfaces through conversation, with every change staying visible and editable inside Joget’s visual builders rather than hidden in generated code.

The webinar is a teaching session, not a takeaway app. Participants who want to rebuild what they saw will need to bring their own LLM API key, the same bring-your-own-key model used across Joget’s AI tools. This approach gives businesses the freedom to connect with their own LLM provider, and puts them in control of their existing data and privacy.

Businesses that want to go further than a single prototype and build full-scale apps and agents that match their enterprise environment will need a Joget platform subscription. Joget’s team is available after the webinar to walk businesses through both.

Submissions for Joget Agent Lab are open now.

Media Contact: pr@joget.com 

About Joget

Joget offers an open-source, enterprise Agentic AI application platform that converges no-code/low-code development with AI agents to help organizations rapidly build and customize enterprise applications at scale. By combining AI agents with visual app builders, not raw code, Joget makes app generation faster, safer, and more accessible for business users and developers alike.

With Generative AI and Agentic AI capabilities, Joget Intelligence enables organizations to automate and enhance processes while maintaining oversight and compliance.

Through Vibe Composition, Joget enables AI-assisted application development where AI interprets business intent and assembles applications using governed, pre-validated composable components. Unlike typical AI code generation, Joget’s visual-first approach ensures applications remain maintainable and governed within collaborative human workflows.

As an Application and Integration Fabric, Joget connects legacy and modern systems seamlessly. Its extensible, open-source core and plugin architecture offer unmatched flexibility, and its White Label solution allows OEMs and digital solution providers to fully rebrand the platform.

Trusted by startups, global enterprises, and government agencies, Joget delivers the speed of AI with the control of visual development for scalable, intelligent digital transformation.

Visit www.joget.com and follow us on LinkedIn, X, Facebook, or YouTube.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/joget-introduces-agent-lab-a-program-helping-businesses-build-ai-agents-without-code-302861032.html

Biosidus expands biologics manufacturing capacity and strengthens global supply capabilities for agalsidase beta

BUENOS AIRES, Argentina, Aug. 26, 2026 /PRNewswire/ — Biosidus, an Argentine biotechnology company with more than four decades of experience in the development and manufacturing of biosimilar medicines, announced that its new bioreactor plant is now operational, increasing the company’s biologics production capacity and reinforcing its ability to support potential international demand.

The expansion strengthens Biosidus’ industrial platform at a time when healthcare systems are placing increasing emphasis on manufacturing reliability, continuity of treatment and diversified sources of complex biologic medicines.

Developed and manufactured in Argentina, Biosidus’ agalsidase beta, its biosimilar enzyme replacement therapy for Fabry disease, represents a significant milestone in the company’s biotechnology platform and its growing focus on treatments for rare diseases.

With additional production capacity, Biosidus is strengthening its international supply capabilities and is prepared to engage with partners and health authorities evaluating sustainable and reliable sources of agalsidase beta supply.

“Continuity of treatment is particularly critical for patients living with rare and chronic diseases. Expanding our productive capacity reinforces our commitment to making Biosidus’ biotechnology capabilities available to healthcare systems seeking sustainable and reliable access to high-quality biologic medicines,” said Mario Koch, Director of Rare Diseases.

After launching agalsidase beta in Argentina in 2025, Biosidus is advancing the international expansion of its program and is available to evaluate extraordinary supply requirements in markets where the applicable regulatory pathways allow it.

The new bioreactor capacity is part of Biosidus’ broader strategy of combining scientific capabilities, local manufacturing, industrial investment and international expansion to increase access to complex biologic therapies.

About Biosidus

Biosidus is an Argentine biotechnology company specializing in the development, manufacturing and commercialization of biosimilar medicines. With more than 40 years of experience in biotechnology and a presence in international markets, the company develops and manufactures complex biologic medicines across multiple therapeutic areas.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/biosidus-expands-biologics-manufacturing-capacity-and-strengthens-global-supply-capabilities-for-agalsidase-beta-302860963.html

Capital Group Announces Appointment of New Chief Information Officer

Guillermo Veiga joins in November from Standard Chartered Bank in Singapore

LOS ANGELES, Aug. 26, 2026 /PRNewswire/ — Capital Group, the world’s largest global active investment manager, announced the appointment of Guillermo Veiga as Chief Information Officer. He will join the company in November, succeeding Marta Zarraga, who will retire at the end of the year. Guillermo will relocate to California from Singapore, where he currently serves as Group Chief Information and Operations Officer at Standard Chartered Bank.

“Technology, data and AI play an increasingly important role in how we deliver investment excellence, serve clients globally and scale our business,” said Rob Klausner, Chief Operating Officer, Capital Group. “Guillermo brings a rare combination of deep technology expertise, operational leadership and global transformation experience. His track record leading large, complex organizations makes him the right leader to help advance Capital’s long-term strategy and position us for the opportunities ahead.”

Born in Uruguay and raised in Spain, Guillermo began his career as a hands-on technologist and has held senior leadership roles across Europe and Asia at Amazon Web Services, Cisco and Banco Santander, pairing deep technical fluency with strong operating experience.

“I was drawn by Capital Group’s long-term commitment to its people and culture paired with its client-centric mindset,” said Guillermo. “Capital is on the cutting edge of technology, and the opportunity to help lead during a period of global expansion for the company, amid the growing ability of data and AI to transform ways of working, is exciting.”

About Capital Group

As Capital Group approaches its 100th anniversary in 2031, its long-term strategy remains firmly rooted in its mission to improve people’s lives through successful investing. With over 9,000 associates and 34 offices around the world, Capital Group manages $3.6 trillion in assets for millions of wealth management and institutional clients around the world*.

*As of June 30, 2026.

© 2026 Capital Group. All rights reserved.

Media contact:

Caroline Semerdjian, Capital Group

Caroline.semerdjian@capgroup.com

(213) 615-3185

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/capital-group-announces-appointment-of-new-chief-information-officer-302860808.html

Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations

Lowest-ever Scope 1 and Scope 2 emissions mark a milestone year in the Company’s SBTi-approved decarbonisation journey

MUMBAI, India, Aug. 26, 2026 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceuticals company, today released its Sustainability Report 2025–26, showcasing significant progress across its environmental, social and governance (ESG) priorities. Anchored by the theme “Advancing Innovation, Leveraging Sustainability,” the report highlights how sustainability continues to be integrated into the Company’s strategy, operations and innovation agenda while creating long-term value for patients, customers, communities and stakeholders.

Key Highlights:

Climate and Responsible Operations

• Achieved a 22.6% reduction in Scope 1 and Scope 2 greenhouse gas emissions compared to the FY2022 baseline
• Increased renewable energy usage to 41% of total energy consumption across operations
• Recycled and reused 2.63 Lakh kilolitres of freshwater, and diverted 65% of total waste for recycling
• Continued progress against the Company’s Science Based Targets initiative (SBTi)-approved decarbonisation roadmap

Quality and Operational Excellence

• Successfully completed 38 regulatory inspections, including three USFDA inspections with zero Official Action Indicated (OAI) observations
• Completed 209 customer audits, reinforcing the Company’s quality and compliance standards across its global manufacturing network
• Advanced enterprise-wide digital transformation through Catalyst NxGen, SAP S/4HANA implementation and expansion of digital quality systems
• Announced a US$90 million investment to expand advanced therapeutics capabilities at its Lexington and Riverview facilities

Governance and People

• Maintained zero data breach incidents and zero corruption cases during the reporting period
• Achieved 100% ESG training completion across employees and 100% Code of Conduct training for the workforce
• Women represented 30% of the Board and 20.1% of the global workforce, reflecting continued progress on diversity and inclusion
• Assessed 38% of critical suppliers against sustainability criteria as part of the Company’s responsible supply chain programme

Community Impact

• During FY2025–26, Piramal Pharma invested ₹8.98 crore in CSR initiatives, positively impacted nearly 1.8 million people across 112 Aspirational Districts through healthcare and education programmes, and continued to strengthen stakeholder engagement through community development, employee well being and responsible business practices.

Nandini Piramal, Chairperson, Piramal Pharma Limited, said, “At Piramal Pharma, we see sustainability not simply as a responsibility, but as a catalyst for innovation, resilience and long-term growth. This means investing in cleaner and more efficient operations, strengthening quality and digital capabilities, developing our people and building deeper partnerships across our value chain.

The progress reflected in this year’s Sustainability Report gives us confidence in the direction we are taking. We believe that innovation and sustainability can reinforce one another, enabling us to make better decisions today while creating greater value for tomorrow.

As we move forward, our focus will remain on turning our sustainability ambitions into measurable action. Our aspiration is to create a future ready organisation that delivers better health outcomes, builds stronger communities and creates enduring value for all our stakeholders.”

The Sustainability Report outlines Piramal Pharma’s long-term sustainability framework, built around four strategic pillars Business Resilience, Quality & Excellence, Responsible Operations, and Stakeholder Centricity supported by more than 50 time-bound sustainability targets across 17 material topics. The Company’s sustainability agenda continues to be overseen by its Sustainability and Risk Management Committee, ensuring ESG considerations remain integral to long-term business performance and value creation.

The Sustainability report follows GRI standards and is aligned with SASB and UNGC frameworks, underscoring PPL’s commitment to sustainable growth, responsible capital allocation, and impactful stakeholder engagement. For more information, please refer to the full report available at – https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/PPL-Sustainability-Report-2025-26.pdf 

About Piramal Pharma Limited

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL’s associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market.

For more information, visit: Piramal Pharma | LinkedIn

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/piramal-pharma-strengthens-future-ready-operations-with-22-6-emissions-reduction-41-renewable-energy-and-zero-usfda-oai-observations-302860704.html

GIGABYTE Partners with AMD to Bring Onimusha: Way of the Sword Game Bundle to Gamers

TAIPEI, Aug. 26, 2026 /PRNewswire/ — GIGABYTE, the world’s leading computer brand, announced the Onimusha: Way of the Sword Game Bundle for eligible graphics cards and gaming desktops powered by the latest AMD technologies. Featuring select products equipped with AMD Radeon™ RX 9070 XT, RX 9070, or RX 9070 GRE graphics, the bundle brings together the AMD RDNA™ 4 architecture, advanced ray tracing, and AMD HYPR-RX technologies with GIGABYTE’s WINDFORCE cooling system and patented Hawk fan to deliver high-performance gaming for the highly anticipated action title.

The GIGABYTE Radeon™ RX 9070 XT, RX 9070, and RX 9070 GRE series graphics cards harness the AMD RDNA™ 4 architecture to deliver enhanced gaming performance and advanced ray tracing for immersive visuals. AMD HYPR-RX further combines performance-enhancing technologies to deliver smoother, more responsive gameplay. Complementing GPU performance, GIGABYTE’s WINDFORCE cooling system incorporates the Hawk fan to increase air pressure by up to 53.6% and air volume by up to 12.5%, supporting stable performance during demanding gaming sessions.

The game bundle is available with selected AORUS PRIME 5 gaming desktops powered by the AMD Ryzen™ 7 9800X3D processor. Designed for high-performance gaming, the AORUS PRIME 5 combines an all-around cooling solution with comprehensive connectivity for a streamlined plug-and-play experience.

From August 25 to September 26, 2026, gamers who purchase eligible GIGABYTE Radeon™ RX 9070 XT, RX 9070, or RX 9070 GRE series graphics cards or selected AORUS PRIME 5 AP551 desktops from participating retailers or e-tailers can receive an Onimusha: Way of the Sword coupon code through AMD. The game launches on September 4, 2026, and coupon codes must be redeemed by October 24, 2026. For more information about the campaign, eligible products, participating retailers, and redemption details, please visit the campaign page.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/gigabyte-partners-with-amd-to-bring-onimusha-way-of-the-sword-game-bundle-to-gamers-302860076.html

Glean:GO Brings Enterprise AI Leaders to San Francisco: NYSE Content Update

NYSE issues a pre-market daily advisory direct from the trading floor.

NEW YORK, Aug. 26, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Ashley Mastronardi delivers the pre-market update on August 26th

• Glean says this week’s conference is a ‘defining moment for enterprise AI.’
  • Founder and CEO Arvind Jain will join NYSE Live to discuss the biggest challenges across AI.
  • Glean plans to introduce its newest offering, which it says is designed to give users the context needed to delegate complex work.
• Lattice acquires Pando in efforts to advance AI-native performance.
  • Lattice CEO Sarah Franklin will join NYSE Live to discuss how the deal advances the company’s investments in workforce intelligence.
  • Pando Founder and CEO Barbra Gago joined Lattice as Chief Marketing + Strategy officer.
• Investors await earnings from NYSX holding Nvidia following market close.
  • Analysts expect the chip giants to report EPS of $2.09 and over $92 billion in revenue during its second quarter.
  • Earlier this morning, the Bureau of Economic Analysis released fresh PCE and GDP data.

Opening Bell

Optimal Tax Asset Management celebrates that launch of OTAX

Closing Bell

Innovative Industrial Properties (NYSE: IIPR) celebrates its 10^th anniversary of listing

For market insights, IPO activity, and today’s opening bell, download the NYSE TV App and check out the NYSE YouTube: TV.NYSE.com and YouTube.com/@NYSEofficial

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/gleango-brings-enterprise-ai-leaders-to-san-francisco-nyse-content-update-302860596.html

PARIS SAINT-GERMAIN AND COCA-COLA RENEW A THREE-YEAR GLOBAL PARTNERSHIP TO BRING FANS TOGETHER AROUND THE WORLD

Paris Saint-Germain and Coca-Cola France are pleased to announce a new global partnership through 2029, marking the return of the collaboration between two of the world’s most recognized brands.

PARIS, Aug. 26, 2026 /PRNewswire/ — Having partnered in the past, Paris Saint-Germain and Coca-Cola are coming together once again to build on their shared history, driven by the same ambition: to bring fans together around their passions and create memorable moments of connection and emotion. At the intersection of football, fashion, music and lifestyle, Paris Saint-Germain has established itself as a cultural reference whose influence extends far beyond the pitch. This naturally resonates with Coca-Cola and its ability to bring communities together around major moments and the passions they share.

This natural connection is at the heart of the renewed partnership. Coca-Cola will once again become an Official Partner of the Club through 2029, with the ambition of creating new experiences for supporters and bringing the excitement of Paris Saint-Germain to life well beyond the football pitch. Powerade, a brand of The Coca-Cola Company portfolio deeply rooted in sports, will also support Paris Saint-Germain through activations centered around athletic performance, energy and pushing beyond limits.

A partnership designed as a global platform for culture and entertainment

Beyond football, Coca-Cola and Paris Saint-Germain intend to tap into the major cultural passions that bring new generations together, creating new ways for fans around the world to experience the Club and connect with one another.

In France, this ambition will come to life throughout the year through fan-focused activations, exclusive experiences and special events designed to bring supporters closer to the moments that matter.

A new Coca-Cola experience at Parc des Princes

As part of the new partnership, Coca-Cola and Paris Saint-Germain will soon unveil a new experiential space at Parc des Princes, designed as a gathering place open to all supporters. Throughout the season, the space will host activations, immersive experiences and exclusive events celebrating football and Parisian culture.

To celebrate the return of the partnership and congratulate Paris Saint-Germain on its 2025–2026 season, Coca-Cola will also launch an exclusive limited-edition collector can featuring the Club’s colors. A total of 400,000 cans will be produced and made available starting October 12 at more than 650 Carrefour stores across the Île-de-France region.¹

“Paris Saint-Germain and Coca-Cola have long shared the same belief: the most powerful emotions are those we experience together. Today, we are proud to write a new chapter in our shared history, with the ambition of creating increasingly innovative, creative and engaging experiences that bring our millions of fans around the world closer together, well beyond football.”

Richard Heaselgrave, Chief Revenue Officer, Paris Saint-Germain

“At Coca-Cola, we have always believed in the power of shared moments. Football is one of its most universal expressions: it brings people together, creates emotion and connects generations. For more than twenty years, we have shared in the collective passion of Paris Saint-Germain fans. This new partnership will allow us to continue creating experiences that build meaningful connections, well beyond the pitch.”

Sébastien Lesage, Director of Sports Partnerships, Coca-Cola Europe

1 – While supplies last

About Paris Saint-Germain

Founded in 1970, Paris Saint-Germain is France’s most successful football club and a leading force in European football, further cemented by its UEFA Champions League victories in 2025 and 2026. Since 2011, under the ownership of Qatar Sports Investments (QSI), the Club has established itself as a leading multi-sport organization spanning men’s and women’s football, handball, judo and esports, driven by values of excellence, teamwork and the pursuit of continuous progress. In 2024, the Club reached another major milestone with the opening of Campus Paris Saint-Germain, its state-of-the-art training center in Poissy.

Deeply rooted in its Parisian identity, Paris Saint-Germain draws on the energy of the French capital to develop a unique model at the intersection of sport, culture and lifestyle. This positioning is reflected in landmark collaborations, including its partnership with Jordan since 2018, as well as numerous projects spanning art, fashion, music and wellness.

With more than 250 million followers across social media and a global network of PSG Academies and supporters’ clubs, Paris Saint-Germain actively contributes to promoting Paris around the world. At the same time, the Club takes tangible action within its local communities through the initiatives of the Paris Saint-Germain Foundation and Endowment Fund, brought together under the PSG for Communities banner to support youth empowerment. Paris Saint-Germain continues to establish itself as the Club of the New Generation.

Contact:

Communicationpsg@psg.fr

About Coca-Cola in France

Coca-Cola® in France is represented by several separate, unaffiliated companies belonging to distinct and independent groups. In mainland France, Coca-Cola Services France provides marketing services related to the promotion of brands owned by The Coca-Cola Company and its affiliates, while beverages marketed under brands owned by The Coca-Cola Company and its affiliates are produced, sold and distributed by Coca-Cola Europacific Partners France in mainland France and by Société Corse de Boissons (SOCOBO) in Corsica.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/paris-saint-germain-and-coca-cola-renew-a-three-year-global-partnership-to-bring-fans-together-around-the-world-302860501.html

G-P Delivers Compliant Global Workforce Intelligence to Enterprise AI Tools

G-P’s new MCP Server securely connects real-time global employment data and insights to Claude, ChatGPT, Gemini and existing corporate agentic workflows

BOSTON, Aug. 26, 2026 /PRNewswire/ — G-P (Globalization Partners), the leader in AI-driven global employment, ranked No. 1 by industry analysts, today announced the launch of its Model Context Protocol (MCP) Server. The new technology enables organizations worldwide to securely stream real-time global workforce data directly into their preferred AI tools, including Anthropic Claude, OpenAI ChatGPT, Google Gemini, Cursor and core HR and payroll systems like Workday, ADP, Paylocity and SAP.

Global workforce data has historically been fragmented across static databases or isolated behind complex API integrations. Introducing AI into global HR and compliance workflows requires rigorous oversight to navigate international labor laws, privacy regulations like GDPR and localized compliance schemas. The G-P MCP Server solves this challenge by serving as an enterprise-grade, secure bridge between an organization’s broader AI ecosystem and G-P’s proprietary global employment infrastructure.

“AI systems are only as reliable as the data and security guardrails behind them,” said GK Konduri, chief product officer at G-P. “With our MCP Server, G-P is enabling true, enterprise-grade agentic workforce management, bringing more than a decade of global HR intelligence and compliance directly into our customers’ existing AI environments. Organizations can now build and deploy powerful, compliant agentic HR workflows inside the AI interfaces their teams already use.”

Powering Real-Time Agentic HR Workflows

G-P’s MCP Server transforms how global HR and People Operations teams access workforce insights. HR professionals can now interact with international workforce data directly inside their preferred AI interfaces turning static employee databases into instant, strategic workflows, including:

• Instant localized reporting: Eliminates hours of manual data aggregation. Simply ask an AI assistant a question such as “Show me a list of EOR employees in Budapest, Hungary with their benefit details” and instantly get a verified table with localized benefit packages and exact costs in local currency backed by G-P deterministic intelligence and local compliance schemas.
• Context-aware follow-ups: HR teams can dive deeper into employee records without re-keying data. Natural follow-up prompts like “How much time off does Sarah Jenkins have?” or “What is her benefits enrollment status?” leverage real-time context without requiring low-level API configurations or repetitive prompting. 
• Automated change management: HR teams can use change request APIs to streamline employee updates, like salary or title changes, by automatically triggering localized compliance workflows powered by G-P’s Global Compliance Engine (GCE). 
• Custom agentic automation: HR operations and People Analytics teams can connect MCP-compatible tools to build tailored HR dashboards, automate routine employee lifecycle tasks and build custom workflows directly within their existing workspaces. 

Enterprise Governance & Security Architecture

Easy to install in any compatible client, the G-P MCP Server ensures high security, data privacy and operational governance across AI interactions:

• Human-in-the-loop guardrails: Built-in safety mechanisms automatically re-route high-risk agentic actions, requiring explicit human review and approval to maintain control and accountability.
• Deep security design: AI agents may only access specific data payloads that the user is authorized to view, with integrated redaction capability.
• Lossless context delivery: Prioritizes complete compliance information delivery with industry leading accuracy and specificity.
• Universal interoperability: Operates seamlessly across any MCP-compatible software suite, transforming general-purpose tools into specialized global workforce intelligence engines with a single click.

By bridging existing enterprise systems with G-P’s deep proprietary global HR, legal and compliance expertise, we continue to set the standard for secure, compliant and scalable global employment. 

To learn more about G-P’s MCP Server and explore G-P’s agentic global employment solutions, visit: globalization-partners.com/g-p-mcp/

About G-P

G-P (Globalization Partners) is the leader in global employment, ranked No. 1 in every industry analyst report. As the world’s first agentic AI-driven Global Employment Platform, G-P codes global labor laws and compliance directly into existing corporate workflows, helping companies of all sizes manage the full employee lifecycle. G-P supports teams in 180+ countries backed by more than a decade of global operational data and the largest team of in-country HR, legal, and compliance experts. This unmatched proprietary knowledge powers its Employer of Record (EOR), Contractor, and Global HR Agent, G-P Gia™, products.

G-P: Global Made Possible™

To learn more, please visit: g-p.com or connect with us via LinkedIn, X, Facebook or check out our Blog.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/g-p-delivers-compliant-global-workforce-intelligence-to-enterprise-ai-tools-302859982.html

IBM Completes Acquisition of HRL Laboratories to Accelerate the Future of Quantum

The combination brings together complementary expertise in quantum computing, sensing, materials science, and advanced technologies to accelerate future innovation

ARMONK, N.Y., Aug. 26, 2026 /PRNewswire/ — IBM (NYSE: IBM) today announced it has completed its acquisition of HRL Laboratories, LLC (HRL), a leading research and development institution whose expertise spans quantum computing, quantum sensing, advanced communications, electronics, manufacturing, and materials science.

The acquisition brings together two leading organizations with a shared commitment to advancing the frontiers of science and technology. HRL’s expertise in silicon-spin qubits complements IBM’s leadership in superconducting quantum computing. HRL also brings capabilities in quantum sensing, quantum materials, cryogenics, control electronics, packaging, and interconnect technologies that are expected to strengthen IBM’s quantum hardware roadmap and support continued innovation across the quantum technology stack.

IBM continues to advance superconducting-qubit architectures through breakthroughs in hardware, error correction, software, and algorithms designed to enable increasingly capable quantum systems. IBM’s roadmap includes its fault-tolerant quantum computer IBM Quantum Starling, expected by 2029 to perform 100 million quantum operations and deliver significantly greater computational capability than today’s quantum computers. Starling is expected to be followed by Blue Jay, IBM’s next-generation fault-tolerant quantum computer, targeted for the mid-2030s.

The acquisition also complements IBM’s broader innovation and investment in quantum manufacturing and infrastructure. HRL’s expertise in silicon-based quantum technologies creates opportunities for future collaboration with Anderon, IBM’s pure-play quantum wafer foundry, supporting scalable manufacturing approaches and accelerating learning cycles across multiple quantum computing modalities.

Boeing and General Motors, HRL’s former owners, will continue to partner with IBM and HRL on quantum applications and advanced technology development.

Financial terms of the transaction were not disclosed.

To learn more about IBM’s acquisition and history of HRL, read here.

About IBM

IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of governments and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM’s long-standing commitment to trust, transparency, responsibility, inclusivity and service. Visit www.ibm.com for more information.

Media contact:

Tim Davidson

IBM

tfdavids@us.ibm.com 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ibm-completes-acquisition-of-hrl-laboratories-to-accelerate-the-future-of-quantum-302859879.html

DarwinHealth Introduces Quantum Cancer Biology: A Cell-State Systems Biology Framework for Precision Oncology

New paradigm integrates single-cell transcriptomics, regulatory network inference, and AI to decode—and therapeutically target—the multiple, co-existing cancer cell states that drive resistance in pancreatic cancer, glioblastoma, and other lethal malignancies

NEW YORK, Aug. 26, 2026 /PRNewswire/ — DarwinHealth, a New York-based, AI-centric biotechnology company. today announced the introduction of Quantum Cancer Biology: A Cell-State Systems Biology Framework for Precision Oncology, a transformative scientific paradigm designed to address one of oncology’s greatest unsolved challenges: why the world’s deadliest cancers continue to evade even the most advanced targeted therapies.

The announcement accompanies the publication in Nature Genetics (https://www.nature.com/articles/s41588-026-02714-8) of a new perspective led by Dr. Andrea Califano and Dr. Kenneth P. Olive, driven by first author Dr. Pasquale Laise, PhD, alongside co-first authors Mikko Turunen, PhD, and Alvaro Curiel-Garcia, PhD.

The study, conducted at Columbia University, presents original research findings and argues that the next revolution in oncology will not come from discovering a single “miracle drug,” but from longitudinally decoding the multiple malignant cellular states that coexist within advanced, treatment-resistant tumors in individual patients.

The framework, undergirded by the company’s proprietary VIPER technology, licensed by Columbia exclusively to DarwinHealth, is supported by pioneering research led by DarwinHealth scientists Pasquale Laise, Mariano J. Alvarez, Andrea Califano, and their collaborators. Their single-cell systems biology studies, including the just published Nature Genetics report, demonstrate that pancreatic cancers comprise not one, but multiple, biologically distinct malignant cell states, each governed by unique regulatory programs and therapeutic vulnerabilities. 

From a landscape-changing perspective, this is the first study to convincingly show that vulnerabilities and desired drug responses among multiple cancer cell states that coexist in an individual patient’s tumor (in this case, pancreatic cancer) are virtually identically conserved in patients with the same kind of cancer. In other words, at the time of disease onset, all patients with a particular kind of cancer—pancreatic cancer, glioblastoma, breast cancer, melanoma, prostate cancer, and many others—harbor a recurring, predictable, and co-existing mix of multiple cancer cell state abnormalities, all of which must be targeted relatively simultaneously to achieve optimal treatment results.

By extension, enduring treatment responses—and most importantly, definitive cures—especially for our most lethal and resistant tumors, will likely come, not from any single bullet, but from decoding the cancer cell states and then deploying multi-drug combinations directed at each abnormal state early in the treatment course. As the study shows, both decoding and targeting strategies can be systematically identified using AI-based algorithms, such as those developed and commercialized by DarwinHealth.

Together, the advances reported in Nature Genetics establish the scientific foundations and drug development roadmaps for a new generation of precision oncology treatments based not simply on identifying genetic mutations, but on decoding the regulatory architecture that determines how every malignant cell behaves—and how it can be therapeutically eliminated. Based on these recent results, as well as previous and yet-to-come studies, these technologies developed and refined by DarwinHealth are paving the way to more universal and more effective combination therapies for cancers shown to be resistant to current treatments and, therefore, responsible for invariably high mortality rates, frequently in excess of 90%.

Beyond Precision Oncology

For decades, precision oncology has largely defined tumors by their genomic mutations, with therapies designed to inhibit individual oncogenic drivers. While this strategy has produced important clinical advances, durable responses in highly resistant cancers such as pancreatic cancer and glioblastoma remain uncommon because tumors continually evolve new, resistant cellular populations.

Quantum Cancer Biology proposes a fundamentally different view.

Rather than treating cancer as a single disease, the framework recognizes each tumor as a dynamic ecosystem composed of multiple interacting malignant cell states. Each cellular state is controlled by its own regulatory circuitry, possesses its own survival mechanisms, and exhibits its own therapeutic sensitivities.

The central challenge, therefore, is not simply identifying a mutation—it is identifying —and in this case, using AI to decode—every clinically relevant cancer cell state within an individual patient’s tumor and determining the optimal therapeutic strategy for each.

DarwinHealth co-founder Califano has also recently published a review in the journal Cell, “Fifteen challenges for generative AI applications to cell biology” (https://www.cell.com/cell/fulltext/S0092-8674(26)00802-0), further illuminating the role of AI for network-based predictions to guide cancer treatment.

Making the Invisible Visible

DarwinHealth’s drug discovery platform leverages single-cell transcriptomics, AI, and regulatory network inference to infer master regulatory protein activity. The company’s technology rigorously validates the functional reality and causality of these cellular states through multi-modal integration with ATAC-seq, lineage tracing, and CRISPR perturbations.

Unlike conventional gene-expression profiling—which merely catalogs transcript abundance—DarwinHealth’s systems biology framework pinpoints the causal drivers maintaining malignant states and identifies the molecular checkpoints most likely to collapse them.

This approach transforms complex tumor landscapes into high-resolution functional maps, revealing previously invisible targets for precision oncology.

Pancreatic Cancer as the Prototype

The power of this approach is illustrated by the original work just published in Nature Genetics.

Using regulatory network analysis of single-cell transcriptomic data, the investigators identified six highly conserved malignant pancreatic cancer cell states organized into three developmental lineages. Importantly, these regulatory states proved remarkably reproducible across independent patient cohorts, pancreatic cancer cell lines, and patient-derived xenograft models, providing a robust mechanistic taxonomy of pancreatic cancer heterogeneity. 

Rather than merely describing tumor diversity, the investigators identified the Master Regulator proteins responsible for maintaining each malignant state and experimentally demonstrated that these regulatory programs represent therapeutically actionable cellular dependencies. 

These findings provide a mechanistic roadmap for developing rational combination therapies capable of simultaneously targeting multiple malignant populations within a single tumor.

Toward Rational Combination Therapy for Cancer

Drug resistance remains the leading cause of mortality in patients with advanced cancer.When one therapeutic agent successfully eliminates drug-sensitive cells, resistant populations frequently survive, expand, and ultimately repopulate the tumor.

Quantum Cancer Biology reframes this problem.

Instead of asking which single drug best treats a tumor, the framework asks:

Which combination of therapeutics is required to eliminate every biologically distinct malignant cell state that exists within that patient’s cancer?

By computationally identifying these states and their regulatory dependencies, DarwinHealth seeks to enable the rational design of multi-agent therapeutic strategies that address the complete cellular architecture of resistant cancers, rather than only their dominant populations. This concept aligns with the company’s broader perspective on treating tumors as complex “oncosystems.” 

Leadership Perspectives

“The future of precision oncology lies in understanding the regulatory logic that determines cellular identity—not merely cataloging mutations or measuring gene expression. By reconstructing the regulatory networks that control individual cancer cell states, we can identify the molecular mechanisms that sustain them and, ultimately, the therapeutic strategies capable of disrupting them.”

— Andrea Califano, Dr.

Co-Founder, DarwinHealth; President, New York Biohub; Clyde and Helen Wu Professor of Chemical Systems Biology, Columbia University

“Single-cell transcriptomics provides unprecedented resolution of tumor heterogeneity, but understanding how those cellular states are established and maintained requires systems-level analysis. By identifying the Master Regulator proteins controlling each malignant state, we can move from describing tumor diversity to defining actionable therapeutic vulnerabilities.”

— Pasquale Laise, PhD

Senior Director, Single-Cell Systems Pharmacology, DarwinHealth

“For decades, oncology has searched for better drugs to treat individual cancers. Quantum Cancer Biology begins with a different premise: that many advanced tumors are not one cancer, but many biologically distinct cancers coexisting within the same patient. Our mission is to decode those hidden cellular states and transform that knowledge into rational—almost invariably, combination—therapeutic strategies that target the full complement of regulatory network derangements.”

— Gideon Bosker, MD

Chief Executive Officer and Co-Founder, DarwinHealth

A New Framework for Precision Oncology

DarwinHealth believes that Quantum Cancer Biology: A Cell-State Systems Biology Framework for Precision Oncology represents a foundational advance in cancer systems biology.

By integrating single-cell transcriptomics, regulatory network inference, inferential artificial intelligence, and systems pharmacology, the framework seeks to identify the smallest rational combination of therapeutic interventions capable of targeting the full spectrum of malignant cellular states within each patient’s tumor.

Initially developed and validated in pancreatic and brain cancer, the framework is now being extended across additional highly resistant malignancies—including glioblastoma and other aggressive solid tumors—with the goal of accelerating the development of more effective precision combination therapies.

As oncology enters an era defined by cellular resolution rather than population averages, DarwinHealth believes Quantum Cancer Biology provides the conceptual and computational foundation for decoding cancer’s hidden complexity—and translating that knowledge into more durable therapeutic outcomes.

About DarwinHealth

Founded by Gideon Bosker and Andrea Califano in 2016, DarwinHealth is a New York City-based precision oncology company pioneering systems biology and artificial intelligence technologies that decode regulatory mechanisms governing cancer. By integrating regulatory network biology, single-cell analysis, and computational pharmacology, DarwinHealth develops predictive technologies to identify patient-specific therapeutic vulnerabilities and accelerate the development of next-generation precision cancer therapies.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/darwinhealth-introduces-quantum-cancer-biology-a-cell-state-systems-biology-framework-for-precision-oncology-302860552.html